Role of 4-1BB (CD 137) in the functional activation of cord blood CD28-CD8+ T cells

Blood

Volumn 100, Issue 9, 2002, Pages 3253-3260

  Kim, Young June ^a   Brutkiewicz, Randy R ^a   Broxmeyer, Hal E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CD137 ANTIGEN; CD28 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 15; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE DIFFERENTIATION; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UMBILICAL CORD BLOOD;

EID: 0036839414     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-11-0136     Document Type: Article

References (60)

1. Trapani JA, Sutton VR, Smyth MJ. CTL granules: Evolution of vesicles essential for combating virus infections. Immunol Today. 1999;20:351-356.
2. Lieberman J, Fabry JA, Kuo MC, et al. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp 160 and reverse transcriptase. J Immunol. 1992;148:2738-2747.
3. Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes antigenic and functional properties. J Immunol. 1993;150:1147-1159.
4. Speiser DE, Vaimori D, Rimoldi D, et al. CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol. 1999;29:1990-1999.
5. Hamann D, Roos MT, van Lier RA. Faces and phases of human CD8 T-cell development. Immunol Today. 1999;20:177-180.
6. Pittet MJ, Speiser DE, Valmori D, et al. Cutting edge: Cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol. 2000;164:1148-1152.
7. Baars PA, Ribeiro Do Couto LM. Leusen JH, et al. Cytolytic mechanisms and expression of activation-regulating receptors on effector-type CD8+CD45RA+CD27- human T cells. J Immunol. 2000;165:1910-1917.
8. - T cells in healthy and immunosuppressed virus carriers. Blood. 2001;98:754-761.
9. Trimble LA, Shankar P, Patterson M, et al. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol. 2000;74:7320-7330.
10. Posnett DN, Edinger JW, Manavalan JS, et al. Differentiation of human CD8 T cells: Implications for in vivo persistence of CD8+ CD28- cytotoxic effector clones. Int Immunol. 1999;11:229-241.
11. Slifka MK, Pagarigan RR, Whitton JL. NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. J Immunol. 2000;164:2009-2015.
12. Shahinian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science. 1993;261:609-612.
13. + T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. Int Immunol. 2000;12:1005-1013.
14. - T-cell selection, function, and death in the primary immune response in vivo. J Clin Invest. 2000;106:1251-1261.
15. Fiorentini S, Licenziati S, Alessandri G, et al. CD11 b expression identifies CD8+CD28- T lymphocytes with phenotype and function of both naive/memory and effector cells. J Immunol. 2001;166:900-907.
16. Kim YJ, Kim SH, Mantel P, et al. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol. 1998;28:881-890.
17. Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol. 1999;11:286-293.
18. + T cell responses. Curr Opin Immunol. 2000;12:448-455
19. Cannons JL, Lau P, Ghumman B, etal. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol. 2001;167:1313-1324.
20. Tan JT, Whitmire JK, Ahmed R, et al. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J Immunol. 1999;163:4859-4868.
21. Tan JT, Whitmire JK, Murali-Krishna K, et al. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol. 2000;164:2320-2325.
22. DeBenedette MA, Wen T, Bachmann MF, et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4 1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol. 1999;163:4833-4841.
23. Strome SE, Martin B, Flies D, et al. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumorreactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9p melanoma. J Immunother. 2000;23:430-437.
24. Sabel MS, Conway TF, Chen FA, et al. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice. J Immunother. 2000;23:362-368.
25. Xiang J. Expression of co-stimulatory 4-1BB ligand induces significant tumor regression and protective immunity. Cancer Biother Radiopharm. 1999;14:353-361.
26. Guinn BA, DeBenedette MA, Watts TH, et al. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a longlasting antitumor vaccine. J Immunol. 1999;162:5003-5010.
27. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3:682-685.
28. Melero I, Bach N, Hellstrom KE, et al. Amplification of tumor immunity by gene transfer of the costimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway. Eur J Immunol. 1998;28:1116-1121.
29. Melero I, Johnston JV, Shufford WW, et al. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190:167-172.
30. Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model. J Natl Cancer Inst. 2000;92:931-936.
31. Chen SH, Pham-Nguyen KB, Martinet O, et al. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol Ther. 2000;2:39-46.
32. Tan JT, Ha J, Cho HR, et al. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses. Transplantation. 2000;70:175-183.
33. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8- T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med, 1997;186:47-55.
34. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, et al. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients, J Immunol. 2001;166:3174-3183.
35. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol. 1999;162:5037-5040,
36. Hurtado JC, Kim YJ, Kwon BS, Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol. 1997;158:2600-2609.
37. Risdon G, Gaddy J, Broxmeyer HE. Allogeneic responses of human umbilical cord blood. Blood Cells. 1994;20:566-570.
38. Garni-Wagner BA, Lee ZH, Kim YJ, etal. 4-1BB is expressed on CD45RAhiROhi transitional T cell in humans. Cell Immunol. 1996;169:91-98.
39. Lee SM, Suen Y, Chang L, et al. Decreased interleukin-12 (IL-12) from activated cord versus adult peripheral blood mononuclear cells and upregulation of interferon-gamma, natural killer, and lymphokine-activated killer activity by IL- 12 in cord blood mononuclear cells. Blood. 1996;88:945-954.
40. Qian JX, Lee SM, Suen Y, et al. Decreased interleukin-15 from activated cord versus adult peripheral blood mononuclear cells and the effect of interleukin-15 in upregulating antitumor immune activity and cytokine production in cord blood. Blood. 1997;90:3106-3117.
41. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: Initial antigen encounter triggers a developmental program in naive cells. Nat Immunol. 2001;2:415-422.
42. Liao F, Rabin RL, Smith CS, et al. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3α. J Immunol. 1999;162:186-194.
43. Snow AL, Chen LJ, Nepomuceno RR, et al. Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol. 2001;167:5404-5411.
44. Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med. 1997;186:1407-1418.
45. Opferman JT, Ober BT, Ashton-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science. 1999;283:1745-1748.
46. Risdon G, Gaddy J, Stehman FB, et al. Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation. Cell Immunol. 1994;154:14-24.
47. Suen Y, Lee SM, Qian J, et al. Dysregulation of lymphokine production in the neonate and its impact on neonatal cell mediated immunity. Vaccine. 1998;16:1369-1377.
48. Broxmeyer HE, Smith FO. Cord blood transplantation. In: Thomas ED, Blume KG, and Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd Ed. Malden, MA: Blackwell Science; 1999:441-443.
49. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000;342:1846-1854.
50. - T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases. J Immunol. 2001;167:4981-4986.
51. Fiorentino S, Dalod M, Olive D, et al. Predominant involvement of CD8+CD28-lymphocytes in human immunodeficiency virus-specific cytotoxic activity. J Viroi. 1996;70:2022-2026.
52. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
53. Borthwick NJ, Bofill M, Gombert WM, et al. Lymphocyte activation in HIV-1 infection, II: Functional defects of CD28- T cells. AIDS. 1994;8:431-441.
54. Appay V, Nixon DF, Donahoe SM, et al. HIV-specific CD8T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000;192:63-75.
55. Goulder PJ, Tang Y, Brander C, et al. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med. 2000;192:1819-1832.
56. - T cell expansions: Evidence for impaired CTL effector function. Eur J Immunol. 2001;31:677-686.
57. Dalod M, Sinet M, Deschemin JC, et al. Altered ex vivo balance between CD28+ and CD28cells within HIV-specific CD8+ T cells of HIV-seropositive patients. Eur J Immunol. 1999;29:38-44.
58. + tumorinfiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol. 2001;167:5042-5051.
59. Kim YJ, Broxmeyer HE. Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8+ T cells. J Hematother Stem Cell Res. 2001;10:441-449.
60. Dunussi-Joannopoulos K, Runyon K, Erickson J, et al. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood. 1999;94:4263-4273